Novocure Ltd (NVCR) — SEC Filings
Novocure Ltd (NVCR) — 36 SEC filings. Latest: 10-Q (Apr 30, 2026). Includes 18 8-K, 7 10-Q, 6 SC 13G/A.
View Novocure Ltd on SEC EDGAR
Overview
Novocure Ltd (NVCR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Apr 30, 2026: NovoCure Ltd. filed its quarterly report on Form 10-Q for the period ending March 31, 2026. The filing includes financial statements and other disclosures relevant to investors. The company's mailing and business address is located at No. 4 The Forum, Grenville Street, St. Helier, Jersey.
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 1 bearish, 34 neutral, 1 mixed. The dominant filing sentiment for Novocure Ltd is neutral.
Filing Type Overview
Novocure Ltd (NVCR) has filed 7 10-Q, 18 8-K, 2 DEF 14A, 2 10-K, 1 8-K/A, 6 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of NVCR's 27 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $167.204M |
| Net Income | -$37.270M |
| EPS | N/A |
| Debt-to-Equity | 2.99 |
| Cash Position | $342.119M |
| Operating Margin | -34.9% |
| Total Assets | $1,361.194M |
| Total Debt | $755.259M |
Key Executives
- Dr. William F. Doyle
- Mr. Joel S. Marcus
- Ms. Ashley L. Rynd
- Dr. William F. Weldon
- Mr. Michael J. Davies
- Ms. Karen L. King
- Abigail P. Johnson
Industry Context
NovoCure operates in the oncology market, specifically focusing on novel therapeutic modalities like Tumor Treating Fields (TTFields). The competitive landscape includes traditional treatments (chemotherapy, radiation, surgery) and emerging therapies. The industry is characterized by high R&D investment, lengthy clinical trial processes, and stringent regulatory hurdles for new drug and device approvals.
Top Tags
10-Q (5) · financials (5) · corporate-governance (5) · financial-reporting (5) · quarterly-report (4) · regulation-fd (4) · corporate-disclosure (4) · amendment (4) · Medical Devices (3) · regulatory-filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Period End Date | 2026-03-31 | The financial and operational data in the report pertains to this date. |
| Filing Date | 2026-04-30 | The date NovoCure Ltd. officially submitted this 10-Q filing to the SEC. |
| Date of Report | 11/24/2025 | Earliest event reported |
| Fiscal Year End | 12/31 | Company's fiscal year end |
| Net revenues for Q3 2025 | $167.204M | Increased from $155.095M in Q3 2024 |
| Net loss for Q3 2025 | $37.270M | Widened from $30.570M net loss in Q3 2024 |
| Net revenues for nine months ended Sep 30, 2025 | $481.003M | Increased from $443.954M in the prior year period |
| Net loss for nine months ended Sep 30, 2025 | $111.728M | Widened from $102.705M net loss in the prior year period |
| Cash and cash equivalents as of Sep 30, 2025 | $342.119M | Increased from $163.767M at Dec 31, 2024 |
| Total liabilities as of Sep 30, 2025 | $1,019.861M | Increased from $880.605M at Dec 31, 2024 |
| Proceeds from senior secured credit facility for Q3 2025 | $99.979M | Contributed to increased cash and cash equivalents |
| Convertible note as of Sep 30, 2025 | $560.620M | Significant component of current liabilities |
| Senior secured credit facility, net as of Sep 30, 2025 | $194.639M | Significant component of long-term liabilities |
| Ordinary shares outstanding as of Sep 30, 2025 | 111,979,981 | Increased from 108,516,819 shares at Dec 31, 2024 |
| Q2 2025 Revenue | $118.5M | 15.3% decrease from Q2 2024 |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant ownership stake in NovoCure Ltd.","entity":"FMR LLC","targetDate":"Next 12 months","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Novocure Ltd (NVCR)?
Novocure Ltd has 36 recent SEC filings from Jan 2024 to Apr 2026, including 18 8-K, 7 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NVCR filings?
Across 36 filings, the sentiment breakdown is: 1 bearish, 34 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Novocure Ltd SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Novocure Ltd (NVCR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Novocure Ltd?
Key financial highlights from Novocure Ltd's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NVCR?
The investment thesis for NVCR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Novocure Ltd?
Key executives identified across Novocure Ltd's filings include Dr. William F. Doyle, Mr. Joel S. Marcus, Ms. Ashley L. Rynd, Dr. William F. Weldon, Mr. Michael J. Davies and 2 others.
What are the main risk factors for Novocure Ltd stock?
Of NVCR's 27 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Novocure Ltd?
Recent forward-looking statements from Novocure Ltd include guidance on {"claim":"FMR LLC will maintain a significant ownership stake in NovoCure Ltd.","entity":"FMR LLC","targetDate":"Next 12.